Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | PRCP | P42785 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13736554 | 0.81 | SLC22A1 (0.56) | SLC22A1PRCPADRB2DRD2KDM1A | |
| SCHEMBL14152143 | 0.80 | SLC22A1 (0.52) | SLC22A1PRCPADRB2DRD2KDM1A | |
| SCHEMBL13735911 | 0.79 | SLC22A1 (0.53) | SLC22A1PRCPADRB2DRD2 | |
| SCHEMBL13736553 | 0.77 | ADRB2 (0.52) | SLC22A1PRCPADRB2DRD2KDM1A | |
| SCHEMBL14152142 | 0.76 | ADRB2 (0.51) | SLC22A1PRCPADRB2DRD2KDM1A | |
| SCHEMBL13736420 | 0.76 | SLC22A1 (0.50) | SLC22A1PRCPADRB2DRD2KDM1A | |
| SCHEMBL13738597 | 0.75 | SLC22A1 (0.49) | SLC22A1PRCPADRB2KDM1A | |
| SCHEMBL13736419 | 0.74 | ADRB2 (0.49) | SLC22A1PRCPADRB2DRD2KDM1A | |
| Water SCHEMBL28203568 | 0.73 | PRCP (0.97) | SLC22A1PRCPADRB2DRD2KDM1A | |
| SCHEMBL10349434 | 0.73 | ADRB2 (0.72) | SLC22A1PRCPADRB2DRD2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309200-B2 | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-04-12 | — | — | US | claimed |
| EP-2707358-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-03-19 | — | — | EP | claimed |
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-12-13 | — | — | US | claimed |
| WO-2012152915-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-15 | — | — | WO | claimed |
| US-9309200-B2 | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9309200-B2 | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-04-12 | — | — | US | disclosed |
| EP-2707358-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-03-19 | — | — | EP | disclosed |
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2012152915-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012152915-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A11, SLC6A1, KCNB2 | SLC22A1 611/4885PRCP 1023/4885ADRB2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.